{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043932","form_type":"8-K","ticker":"ANIX","cik":"0000715446","company_name":"Anixa Biosciences Inc","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.797218+00:00","generated_at":"2026-06-07T16:36:02.014935+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Anixa reports positive Phase 1 breast cancer vaccine data; T-cell responses in 75% of patients","bullets":["16 TNBC patients treated; 12/16 (75%) developed antigen-specific T-cell responses at all dose levels.","Statistically significant increases in IFNγ (P=0.03) and IL-17 (P=0.0001) over baseline.","Dose Level 1 determined as immunologic and maximum tolerated dose; no serious adverse events besides injection site irritation.","Plans to evaluate vaccine with Keytruda in residual disease cohort and in BRCA/PALB2 mutation carriers.","CEO says data exceeded expectations; Phase 2/3 planning underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043932","json":"https://secwatch.observer/filing/0001493152-23-043932.json","markdown":"https://secwatch.observer/filing/0001493152-23-043932.md","text":"https://secwatch.observer/filing/0001493152-23-043932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/0001493152-23-043932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/715446/000149315223043932/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:36:02.014935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}